What is the number of replacement orders in the quarter
ew center. I think it might be helpful just to kind of help us get our arms around the China opportunity.
Sorry, it's a little bit of a broad question but how do you see that channel evolving? And any updates maybe you could share or just remind us of the installed base today. Can China be as big of an opportunity as Europe or the U.S. over time? And what's the approval pathway and or any timing, maybe too early for timing, but for Genesis in China? Thanks for taking all the questions, David.
David Fischel -- Chairman and Chief Executive Officer
Sure. Thanks a lot. It's actually a great question. And overall, China still is a small, small part of our overall business.
We have about five systems there. So it's kind of single-digit market share from an installed base perspective and -- but what we've seen in China is a lot of engagement with the physicians and customers there. Both in terms of their procedure volumes, they're highly, highly active and I think that's partially also driven by robotics. Enabling many more physicians there to do cardiac ablation procedures where otherwise they didn't have -- they didn't receive the training, or they didn't have the ability to do complex cardiac ablation procedures.
The training programs for electrophysiology there are still kind of less refined and kind of in the U.S. or Europe. And so we've seen kind of very high utilization of our systems in China and we've also seen kind of other companies which are kind of interested in working with us in China. And so we're going to be kind of prudent in anything we do and we don't kind of -- we will kind of advance things in a prudent fashion there.
But overall, I kind of a sense that there are actually very good opportunities in China to grow a robust kind of business and to collaborate with others. And I hope we'll be able to kind of provide more updates in the coming quarters.
Operator
Thank you. [Operator instructions] We will take our next question from Jason Wittes with Northland. Please go ahead.
Jason Wittes -- Northland -- Analyst
Hi, thanks for taking the question. First off, you mentioned that you had an existing customer who had an order for a Genesis system. It sounds like that's not a replacement, that's an addition. Do I have that correct? And what are they doing with their old Niobe system?
David Fischel -- Chairman and Chief Executive Officer
No, so that is a replacement.
Jason Wittes -- Northland -- Analyst
Oh, that is a replacement. OK, so you do have one replacement booked this year thus far? Just to be clear. And --
David Fischel -- Chairman and Chief Executive Officer
And we have really -- we have one replacement that -- one of the five orders that we discussed last time was a replacement cycle order in Europe. And this is now the second replacement cycle, which is the first one in the U.S.
Jason Wittes -- Northland -- Analyst
OK. Thanks for clarifying. And then, related to that, you said it sounds like they're also looking to add an additional system. Did I hear that correct?
David Fischel -- Chairman and Chief Executive Officer
There's language in the contract which makes it likely that the hospital system will acquire an additional rollout this year. 
Jason Wittes -- Northland -- Analyst
OK. And then, you know, related to the third -- I think you mentioned it was 38 contacts and 20 visits this quarter. In terms of a breakout, in terms of what our new customers, what our existing customers, can you give us a sense of what that might look like?
David Fischel -- Chairman and Chief Executive Officer
Sure. So yeah, it was 38 individuals on 23 separate TeleRobotic test drive visits. And 30% of those visits, so I think it was seven of them, were first discussions with greenfield opportunities.
Jason Wittes -- Northland -- Analyst
OK. I think that's similar to what you were seeing last year or is it slightly different? 
David Fischel -- Chairman and Chief Executive Officer
Yeah, the rate is overall similar. You're correct. 
Jason Wittes -- Northland -- Analyst
OK. And then you mentioned, kind of your longer-term strategy
ew center. I think it might be helpful just to kind of help us get our arms around the China opportunity.
Sorry, it's a little bit of a broad question but how do you see that channel evolving? And any updates maybe you could share or just remind us of the installed base today. Can China be as big of an opportunity as Europe or the U.S. over time? And what's the approval pathway and or any timing, maybe too early for timing, but for Genesis in China? Thanks for taking all the questions, David.
David Fischel -- Chairman and Chief Executive Officer
Sure. Thanks a lot. It's actually a great question. And overall, China still is a small, small part of our overall business.
We have about five systems there. So it's kind of single-digit market share from an installed base perspective and -- but what we've seen in China is a lot of engagement with the physicians and customers there. Both in terms of their procedure volumes, they're highly, highly active and I think that's partially also driven by robotics. Enabling many more physicians there to do cardiac ablation procedures where otherwise they didn't have -- they didn't receive the training, or they didn't have the ability to do complex cardiac ablation procedures.
The training programs for electrophysiology there are still kind of less refined and kind of in the U.S. or Europe. And so we've seen kind of very high utilization of our systems in China and we've also seen kind of other companies which are kind of interested in working with us in China. And so we're going to be kind of prudent in anything we do and we don't kind of -- we will kind of advance things in a prudent fashion there.
But overall, I kind of a sense that there are actually very good opportunities in China to grow a robust kind of business and to collaborate with others. And I hope we'll be able to kind of provide more updates in the coming quarters.
Operator
Thank you. [Operator instructions] We will take our next question from Jason Wittes with Northland. Please go ahead.
Jason Wittes -- Northland -- Analyst
Hi, thanks for taking the question. First off, you mentioned that you had an existing customer who had an order for a Genesis system. It sounds like that's not a replacement, that's an addition. Do I have that correct? And what are they doing with their old Niobe system?
David Fischel -- Chairman and Chief Executive Officer
 No, so that is a replacement.
Jason Wittes -- Northland -- Analyst
Oh, that is a replacement. OK, so you do have one replacement booked this year thus far? Just to be clear. And --
David Fischel -- Chairman and Chief Executive Officer
And we have really -- we have one replacement that -- one of the five orders that we discussed last time was a replacement cycle order in Europe. And this is now the second replacement cycle, which is the first one in the U.S.
Jason Wittes -- Northland -- Analyst
OK. Thanks for clarifying. And then, related to that, you said it sounds like they're also looking to add an additional system. Did I hear that correct?
David Fischel -- Chairman and Chief Executive Officer
There's language in the contract which makes it likely that the hospital system will acquire an additional rollout this year. 
Jason Wittes -- Northland -- Analyst
OK. And then, you know, related to the third -- I think you mentioned it was 38 contacts and 20 visits this quarter. In terms of a breakout, in terms of what our new customers, what our existing customers, can you give us a sense of what that might look like?
David Fischel -- Chairman and Chief Executive Officer
Sure. So yeah, it was 38 individuals on 23 separate TeleRobotic test drive visits. And 30% of those visits, so I think it was seven of them, were first discussions with greenfield opportunities.
Jason Wittes -- Northland -- Analyst
OK. I think that's similar to what you were seeing last year or is it slightly different? 
David Fischel -- Chairman and Chief Executive Officer
Yeah, the rate is overall similar. You're correct. 
Jason Wittes -- Northland -- Analyst
OK. And then you mentioned, kind of your longer-term strategy